Kodiak(US:KOD) Prnewswire·2026-03-26 10:00Core Insights - Kodiak Sciences announced positive topline results from the GLOW2 Phase 3 study, demonstrating the superiority of Zenkuda (tarcocimab tedromer) over sham treatment in patients with diabetic retinopathy [1][3][4] Company Overview - Kodiak Sciences is a precommercial biotechnology company focused on developing transformative therapeutics for retinal diseases, with Zenkuda being a key product in their pipeline [1][26] - The company is advancing multiple late-stage clinical programs, including Zenkuda for diabetic retinopathy, retinal vein occlusion, and wet AMD [26] Study Results - In the GLOW2 study, 62.5% of patients treated with Zenkuda achieved a 2-step improvement in the Diabetic Retinopathy Severity Score (DRSS) at Week 48, compared to 3.3% in the sham group, achieving statistical significance (p<0.0001) [3][5][20] - Zenkuda also showed an 85% reduction in the risk of developing sight-threatening complications compared to sham (2.4% with Zenkuda vs 15.8% with sham, p=0.0001) [3][10][20] - The study included a diverse patient population, including those using GLP-1 medications, and demonstrated consistent efficacy across different patient demographics [7][31] Safety Profile - Zenkuda was well-tolerated, with a 0% rate of intraocular inflammation and a 2.3% cataract adverse event rate, comparable to the sham group [3][6][12] - The safety data supports the established safety profile of Kodiak's Antibody Biopolymer Conjugate (ABC®) platform [3][12] Future Plans - Based on the strong results from GLOW2, Kodiak intends to accelerate the Biologics License Application (BLA) submission timeline for Zenkuda [11][12] - The company is also exploring other therapies based on the ABC platform, including KSI-501 and KSI-101, with potential BLA submissions anticipated in 2026 [12][26]